{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:11:56Z","timestamp":1792793516169,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Diagnosing Alzheimer\u2019s disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. Plasma p-tau217 discriminated cognitively stable individuals with DS from those with AD dementia with an AUC of 0.96 (95% CI, 0.95-0.97), and from those with prodromal AD with an AUC of 0.90 (95% CI, 0.87-0.92). Amyloid \u03b2 (A\u03b2) positive and A\u03b2 negative individuals with DS were distinguished with an AUC of 0.95 (95% CI, 0.92-0.99). In this study, we demonstrate that plasma p-tau217 is highly accurate in detecting amyloid \u03b2 positivity and predicting clinical progression in individuals with DS, outperforming other plasma biomarkers. These findings support its use as a reliable, noninvasive tool for early AD detection and management in individuals with DS.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-65882-x","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T15:55:31Z","timestamp":1762790131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Plasma p-tau217 as a biomarker of Alzheimer\u2019s disease pathology in individuals with Down syndrome"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3080-6870","authenticated-orcid":false,"given":"Hanna","family":"Huber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0891-1215","authenticated-orcid":false,"given":"Javier","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Leuzy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Kittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5339-933X","authenticated-orcid":false,"given":"Guglielmo","family":"di Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bessy","family":"Benejam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-8465","authenticated-orcid":false,"given":"Laura","family":"Videla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Barroeta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura del Hoyo","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5643-7971","authenticated-orcid":false,"given":"Luc\u00eda","family":"Maure-Blesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3039-9115","authenticated-orcid":false,"given":"\u00cd\u00f1igo","family":"Rodr\u00edguez-Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Enrique","family":"Arriola Infante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ill\u00e1n-Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9958-0951","authenticated-orcid":false,"given":"Alexandre","family":"Bejanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7684-6318","authenticated-orcid":false,"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2568-5478","authenticated-orcid":false,"given":"Alberto","family":"Lle\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Carmona-Iragui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-3245","authenticated-orcid":false,"given":"Daniel","family":"Alcolea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3930-4354","authenticated-orcid":false,"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1340-638X","authenticated-orcid":false,"given":"Juan","family":"Fortea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3579-8804","authenticated-orcid":false,"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"65882_CR1","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S1474-4422(21)00245-3","volume":"20","author":"J Fortea","year":"2021","unstructured":"Fortea, J. et al. Alzheimer\u2019s disease associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 20, 930\u2013942 (2021).","journal-title":"Lancet Neurol."},{"key":"65882_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.dhjo.2020.100947","volume":"13","author":"SD Landes","year":"2020","unstructured":"Landes, S. D., Stevens, J. D. & Turk, M. A. Cause of death in adults with Down syndrome in the United States. Disabil. Health J. 13, 100947 (2020).","journal-title":"Disabil. Health J."},{"key":"65882_CR3","doi-asserted-by":"publisher","first-page":"e2212910","DOI":"10.1001\/jamanetworkopen.2022.12910","volume":"5","author":"MF Iulita","year":"2022","unstructured":"Iulita, M. F. et al. Association of Alzheimer disease with life expectancy in people with Down syndrome. JAMA Netw. open. 5, e2212910 (2022).","journal-title":"JAMA Netw. open."},{"key":"65882_CR4","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/jir.12390","volume":"61","author":"M McCarron","year":"2017","unstructured":"McCarron, M. et al. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J. Intellect. Disabil. Res. Jidr. 61, 843\u2013852 (2017).","journal-title":"J. Intellect. Disabil. Res. Jidr."},{"key":"65882_CR5","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea, J. et al. Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet 395, 1988\u20131997 (2020).","journal-title":"Lancet"},{"key":"65882_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/nrn3983","volume":"16","author":"FK Wiseman","year":"2015","unstructured":"Wiseman, F. K. et al. A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome. Nat. Rev. Neurosci. 16, 564\u2013574 (2015).","journal-title":"Nat. Rev. Neurosci."},{"key":"65882_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41582-018-0132-6","volume":"15","author":"IT Lott","year":"2019","unstructured":"Lott, I. T. & Head, E. Dementia in Down syndrome: unique insights for Alzheimer disease research. Nat. Rev. Neurol. 15, 135\u2013147 (2019).","journal-title":"Nat. Rev. Neurol."},{"key":"65882_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S1474-4422(22)00408-2","volume":"22","author":"AH Boerwinkle","year":"2023","unstructured":"Boerwinkle, A. H. et al. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer\u2019s disease: a cross-sectional study. Lancet Neurol. 22, 55\u201365 (2023).","journal-title":"Lancet Neurol."},{"key":"65882_CR9","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/bs.irrdd.2022.05.006","volume":"62","author":"V Fleming","year":"2022","unstructured":"Fleming, V. et al. Cognitive outcome measures for tracking Alzheimer\u2019s disease in Down syndrome. Int. Rev. Res. Dev. Disabil. 62, 227\u2013263 (2022).","journal-title":"Int. Rev. Res. Dev. Disabil."},{"key":"65882_CR10","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.3390\/jcm10163639","volume":"10","author":"L Montoliu-Gaya","year":"2021","unstructured":"Montoliu-Gaya, L., Strydom, A., Blennow, K., Zetterberg, H. & Ashton, N. J. Blood biomarkers for Alzheimer\u2019s disease in Down syndrome. JCM 10, 3639 (2021).","journal-title":"JCM"},{"key":"65882_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104547","volume":"90","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya, L. et al. Plasma and cerebrospinal fluid glial fibrillary acidic protein levels in adults with Down syndrome: a longitudinal cohort study. eBioMedicine 90, 104547 (2023).","journal-title":"eBioMedicine"},{"key":"65882_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105327","volume":"108","author":"M Carmona-Iragui","year":"2024","unstructured":"Carmona-Iragui, M. et al. Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer\u2019s disease and Down syndrome. eBioMedicine 108, 105327 (2024).","journal-title":"eBioMedicine"},{"key":"65882_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.nicl.2017.10.022","volume":"17","author":"N Neale","year":"2018","unstructured":"Neale, N., Padilla, C., Fonseca, L. M., Holland, T. & Zaman, S. Neuroimaging and other modalities to assess Alzheimer\u2019s disease in Down syndrome. NeuroImage Clin. 17, 263\u2013271 (2018).","journal-title":"NeuroImage Clin."},{"key":"65882_CR14","first-page":"403","volume":"12","author":"RL Henson","year":"2020","unstructured":"Henson, R. L. et al. Cerebrospinal fluid biomarkers of Alzheimer\u2019s disease in a cohort of adults with Down syndrome. Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit. 12, 403 (2020).","journal-title":"Alzheimer\u2019s Dement. Diagn. Assess. Dis. Monit."},{"key":"65882_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea, J. et al. Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol. 17, 860\u2013869 (2018).","journal-title":"Lancet Neurol."},{"key":"65882_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24319-x","volume":"12","author":"A Lle\u00f3","year":"2021","unstructured":"Lle\u00f3, A. et al. Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome. Nat. Commun. 12, 622 (2021).","journal-title":"Nat. Commun."},{"key":"65882_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-70719-2","volume":"10","author":"Gonzalo-Calvo","year":"2020","unstructured":"Gonzalo-Calvo .et al. Evaluation of biochemical and hematological parameters in adults with Down syndrome. Sci. Rep. 10, 13755 (2020).","journal-title":"Sci. Rep."},{"key":"65882_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","volume":"81","author":"NJ Ashton","year":"2024","unstructured":"Ashton, N. J. et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. JAMA Neurol. 81, 255 (2024).","journal-title":"JAMA Neurol."},{"key":"65882_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1522434","volume":"17","author":"L Del Hoyo Soriano","year":"2025","unstructured":"Del Hoyo Soriano, L., Wagemann, O., Bejanin, A., Levin, J. & Fortea, J. Sex-related differences in genetically determined Alzheimer\u2019s disease. Front. Aging Neurosci. 17, 1522434 (2025).","journal-title":"Front. Aging Neurosci."},{"key":"65882_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad074","volume":"5","author":"MF Iulita","year":"2023","unstructured":"Iulita, M. F. et al. Association of biological sex with clinical outcomes and biomarkers of Alzheimer\u2019s disease in adults with Down syndrome. Brain Commun. 5, fcad074 (2023).","journal-title":"Brain Commun."},{"key":"65882_CR21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein, S. et al. Two randomized phase 3 studies of Aducanumab in early Alzheimer\u2019s disease. J. Prev. Alzheimer\u2019s Dis. 9, 197\u2013210 (2022).","journal-title":"J. Prev. Alzheimer\u2019s Dis."},{"key":"65882_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck, C. H. et al. Lecanemab in early Alzheimer\u2019s disease. N. Engl. J. Med. 388, 9\u201321 (2023).","journal-title":"N. Engl. J. Med."},{"key":"65882_CR23","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1001\/jama.2023.22924","volume":"330","author":"MS Rafii","year":"2023","unstructured":"Rafii, M. S. & Fortea, J. Down syndrome in a new era for Alzheimer disease. JAMA 330, 2157 (2023).","journal-title":"JAMA"},{"key":"65882_CR24","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772 (2020).","journal-title":"JAMA"},{"key":"65882_CR25","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70172","volume":"21","author":"PR Kac","year":"2025","unstructured":"Kac, P. R. et al. Plasma p-tau212 as a biomarker of sporadic and Down syndrome Alzheimer\u2019s disease. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 21, e70172 (2025).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"65882_CR26","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1001\/jamaneurol.2022.1740","volume":"79","author":"S Janelidze","year":"2022","unstructured":"Janelidze, S. et al. Detection of brain tau pathology in Down syndrome using plasma biomarkers. JAMA Neurol. 79, 797\u2013807 (2022).","journal-title":"JAMA Neurol."},{"key":"65882_CR27","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S1474-4422(25)00158-9","volume":"24","author":"S Janelidze","year":"2025","unstructured":"Janelidze, S. et al. Prediction of amyloid and tau brain deposition and cognitive decline in people with Down syndrome using plasma biomarkers: a longitudinal cohort study. Lancet Neurol. 24, 591\u2013600 (2025).","journal-title":"Lancet Neurol."},{"key":"65882_CR28","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S1474-4422(24)00084-X","volume":"23","author":"JK Wisch","year":"2024","unstructured":"Wisch, J. K. et al. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer\u2019s disease: a cross-sectional study. Lancet Neurol. 23, 500\u2013510 (2024).","journal-title":"Lancet Neurol."},{"key":"65882_CR29","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S1474-4422(24)00426-5","volume":"23","author":"EK Schworer","year":"2024","unstructured":"Schworer, E. K. et al. Timeline to symptomatic Alzheimer\u2019s disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study. Lancet Neurol. 23, 1214\u20131224 (2024).","journal-title":"Lancet Neurol."},{"key":"65882_CR30","doi-asserted-by":"publisher","first-page":"e2435018","DOI":"10.1001\/jamanetworkopen.2024.35018","volume":"7","author":"E Rubenstein","year":"2024","unstructured":"Rubenstein, E. et al. Alzheimer dementia among individuals with Down syndrome. JAMA Netw. Open. 7, e2435018 (2024).","journal-title":"JAMA Netw. Open."},{"key":"65882_CR31","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/j.neuron.2024.01.024","volume":"112","author":"C Lopez-Lee","year":"2024","unstructured":"Lopez-Lee, C., Torres, E. R. S., Carling, G. & Gan, L. Mechanisms of sex differences in Alzheimer\u2019s disease. Neuron 112, 1208\u20131221 (2024).","journal-title":"Neuron"},{"key":"65882_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41582-018-0032-9","volume":"14","author":"MT Ferretti","year":"2018","unstructured":"Ferretti, M. T. et al. Sex differences in Alzheimer disease-the gateway to precision medicine. Nat. Rev. Neurol. 14, 457\u2013469 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"65882_CR33","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/ene.14174","volume":"27","author":"MT Ferretti","year":"2020","unstructured":"Ferretti, M. T. et al. Sex and gender differences in Alzheimer\u2019s disease: current challenges and implications for clinical practice: position paper of the dementia and cognitive disorders panel of the European Academy of Neurology. Eur. J. Neurol. 27, 928\u2013943 (2020).","journal-title":"Eur. J. Neurol."},{"key":"65882_CR34","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70259","volume":"21","author":"L Videla","year":"2025","unstructured":"Videla, L. et al. The Down Alzheimer Barcelona neuroimaging initiative (DABNI) and its contributions to understanding Alzheimer\u2019s disease in Down syndrome: a decade of discovery. Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc. 21, e70259 (2025).","journal-title":"Alzheimer\u2019s Dement. J. Alzheimer\u2019s Assoc."},{"key":"65882_CR35","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.trci.2019.09.005","volume":"5","author":"D Alcolea","year":"2019","unstructured":"Alcolea, D. et al. The Sant Pau initiative on neurodegeneration (SPIN) cohort: a data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer\u2019s Dement. 5, 597\u2013609 (2019).","journal-title":"Alzheimer\u2019s Dement."},{"key":"65882_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton, N. J. et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 141, 709\u2013724 (2021).","journal-title":"Acta Neuropathol."},{"key":"65882_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1515\/cclm-2021-0651","volume":"60","author":"J Gobom","year":"2022","unstructured":"Gobom, J. et al. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clin. Chem. Lab. Med. 60, 207\u2013219 (2022).","journal-title":"Clin. Chem. Lab. Med."},{"key":"65882_CR38","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1186\/s13195-019-0478-z","volume":"11","author":"G Salvad\u00f3","year":"2019","unstructured":"Salvad\u00f3, G. et al. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers. Alzheimer's Res. Ther. 11, 357 (2019).","journal-title":"Alzheimer's Res. Ther."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65882-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65882-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T04:44:38Z","timestamp":1763181878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65882-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65882"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65882-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Ll\u00e9o has served as a consultant or on advisory boards for Almirall, Fujirebio-Europe, Roche, Biogen, Grifols, Novartis, Eisai, Lilly, and Nutricia outside the submitted work. M.C.I. has served on an advisory board for Roche and has received honoraria for educational events from Esteve, Lilly, Neuraxpharm, Roche and Adium pharma outside the submitted work. D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmac\u00e9utica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals SA outside the submitted work. D.A., A Ll\u00e9o and J.F. report holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0; WO2019175379 A1) outside of the submitted work. K.B. has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, Roche, and WebMD, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program outside the submitted work. J.F. reported serving on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Alnylam, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zamb\u00f3n, Spanish Neurological Society, T21 Research Society, Lumind Foundation, J\u00e9r\u00f4me-Lejeune Foundation, Alzheimer\u2019s Association, National Institutes of Health USA, and Instituto de Salud Carlos III outside the submitted work. J.F. reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). N.J.A. has served at scientific advisory boards or has given lectures sponsored by Biogen, Eli-Lilly, Quanterix, VJ Dementia and Roche outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9900"}}